[1]李 欢,罗 静,藕顺龙,等.肿瘤患者经济毒性评估工具的系统评价[J].卫生经济研究,2026,43(09):49-55.
　LI Huan,LUO Jing,OU Shunlong,et al.Systematic Review of Oncology-Related Financial Toxicity Assessment Tools[J].Journal Press of Health Economics Research,2026,43(09):49-55.
点击复制

肿瘤患者经济毒性评估工具的系统评价

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年09期
页码:
49-55
栏目:
经济学评价
出版日期:
2026-09-02

文章信息/Info

Title:
Systematic Review of Oncology-Related Financial Toxicity Assessment Tools
作者:
李 欢1; 罗 静2; 藕顺龙3; 郑冬妮4; 1; 蒋 倩3
1.电子科技大学医学院，四川省肿瘤医院·研究所，四川 成都 610054
2.宜宾市第二人民医院，四川 宜宾 644000
3.四川省肿瘤医院·研究所，四川省肿瘤临床医学研究中心，四川省癌症防治中心，电子科技大学附属肿瘤医院，四川 成都 610041
4.成都市第五人民医院，四川 成都 611130
Author(s):
LI Huan;  LUO Jing;  OU Shunlong;  ZHENG Dongni;  JIANG Qian
School of Medicine, University of Electronic Science and Technology of China / Sichuan Cancer Hospital & Institute, Chengdu Sichuan 610054, China
关键词:
肿瘤患者; 经济毒性; 评估工具; 系统评价
Keywords:
oncology patients;  financial toxicity;  assessment tools;  systematic review
分类号:
R19
文献标志码:
A
摘要:
目的：系统评价肿瘤患者经济毒性评估工具的基本特征、评价维度、方法学质量及测量学属性等关键要素，为选择使用或科学构建适合我国国情的评估工具提供参考。方法：检索The Cochrane Library等数据库，对肿瘤患者经济毒性评估工具相关文献进行分析，重点比较评估工具的评价维度、方法学质量、测量学属性等关键要素。结果：共纳入28个肿瘤患者经济毒性评估工具，大多由国外学者开发，国内研究相对滞后；28个评估工具涵盖15个评价条目，评价维度多元，测量学属性各异。结论：现有肿瘤患者经济毒性评估工具的适用性存在局限，方法学一致性有待提升；亟待开发出适合我国国情的经济毒性评估工具，为临床医护人员有效识别经济毒性风险提供依据。
Abstract:
Objective To conduct a systematic review of the fundamental characteristics, assessment dimensions, development methodologies, and psychometric properties of global oncology-related financial toxicity assessment tools, and provide a reference for selecting or scientifically developing localized assessment tools suitable for China's conditions. Methods A comprehensive search was performed across the databases including the Cochrane Library, and relevant literature on oncology-related financial toxicity assessment tools was analyzed. Key elements, specifically financial toxicity assessment dimensions, development methodologies, and psychometric properties, were emphasized for comparative analysis. Results A total of 28 oncology-related financial toxicity assessment tools were included, most were developed by foreign researchers, while domestic research lags behind. The 28 tools covered 15 assessment items, featuring diverse assessment dimensions and varying psychometric properties. Conclusion The existing oncology-related financial toxicity assessment tools demonstrate limitations in applicability and exhibit inconsistencies in assessment dimensions. There is an urgent need to develop oncology-related financial assessment tools tailored to China's cultural context to provide a basis for clinical healthcare professionals to effectively identify financial toxicity risks.

参考文献/References:

[1] Zafar S Y, Abernethy A P. Financial toxicity, part I: a new name for a growing problem[J]. Oncology (Williston Park, N.Y.), 2013, 27(02): 80-81, 149.
[2] Xu B, So W K W, Choi K C, et al. Financial toxicity and its risk factors among patients with cancer in China: A nationwide multisite study[J]. Asia-Pacific Journal of Oncology Nursing, 2024, 11(05): 100443.
[3] Sturgeon C. The financial burden of cancer in the united states[J]. Endocrinology and Metabolism Clinics of North America, 2025, 54(03): 455-467.
[4] Wright E P, Kiely M, Johnston C, et al. Development and evaluation of an instrument to assess social difficulties in routine oncology practice[J]. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 2005, 14(02): 373-386.
[5] Sharp L, Carsin A E, Timmons A. Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer[J]. Psycho-Oncology, 2013, 22(04): 745-755.
[6] de Souza J A, Yap B J, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)[J]. Cancer, 2017, 123(03): 476-484.
[7] de Souza J A, Yap B J, Hlubocky F J, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure[J]. Cancer, 2014, 120(20): 3245-3253.
[8] Khera N. Reporting and grading financial toxicity[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2014, 32(29): 3337-3338.
[9] Riva S, Arenare L, Di Maio M, et al. Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system[J]. BMJ open, 2021, 11(10): e049128.
[10] Guy G P, Ekwueme D U, Yabroff K R, et al. Economic burden of cancer survivorship among adults in the United States[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2013, 31(30): 3749-3757.
[11] Wang L ling, Xu R H. Development of a rapid tool for screening financial toxicity based on the comprehensive score for financial toxicity[J]. Journal of Cancer Policy, 2024, 40: 100475.
[12] Richter L, Pauge S, Mehlis K, et al. Measuring financial distress in german cancer patients: development and validation of the financial distress of cancer assessment tool (FIAT)[J]. ESMO Open, 2024, 9(12): 103992.
[13] Thom B, Tin A L, Chino F, et al. Development and validation of a simplified financial toxicity screening tool for use in clinical practice[J]. JCO Oncology Practice, 2025, 21(01): 12-19.
[14] Badr H, Han J, Mims M. Development and validation of FinTox: a new screening tool to assess cancer-related financial toxicity[J]. Cancer Medicine, 2024, 13(15): e7306.
[15] Financial toxicity(financial distress) and cancer treatment-NCI[EB/OL]. (2017-06-29)[2025-12-22]. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-pdq.
[16] Meneses K, Azuero A, Hassey L, et al. Does economic burden influence quality of life in breast cancer survivors?[J]. Gynecologic Oncology, 2012, 124(03): 437-443.
[17] Huang H, Yang Z, Chen X, et al. A novel clinical assessment scale for evaluating financial toxicity in breast cancer patients[J]. The Lancet Regional Health-Western Pacific, 2025, 55: 101410.
[18] Gharzai L A, Ryan K A, Szczygiel L, et al. Financial toxicity during breast cancer treatment: a qualitative analysis to inform strategies for mitigation[J]. JCO oncology practice, 2021, 17(10): e1413-e1423.
[19] Cdc. Meetings of the advisory committee on breast cancer in young women[EB/OL]. (2025-03-03)[2025-12-21]. https://www.cdc.gov/breast-cancer/php/advisory-committee/meetings.html.
[20] Hueniken K, Douglas C M, Jethwa A R, et al. Measuring financial toxicity incurred after treatment of head and neck cancer: development and validation of the financial index of toxicity questionnaire[J]. Cancer, 2020, 126(17): 4042-4050.
[21] 苏明珠.基于患者报告结局的老年癌症经济毒性评估工具开发及初步验证研究[D].济南：山东大学，2023.
[22] Liu L, Zhang A, Su M, et al. The development and validation of a patient-reported outcome measure to assess financial hardship among older cancer survivors in China: hardship and recovery with distress survey[J]. Frontiers in Oncology, 2023, 13: 1151465.
[23] Dar M A, Chauhan R, Murti K, et al. Development and validation of subjective financial distress questionnaire(SFDQ): a patient reported outcome measure for assessment of financial toxicity among radiation oncology patients[J]. Frontiers in Oncology, 2021, 11: 819 313.
[24] Financial toxicity and cancer treatment(PDQR) - NCI[EB/OL]. (2016-08-26)[2025-12-22]. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-hp-pdq.
[25] 刘艳玲，豆艳，刘位真.癌症家庭照顾者经济毒性量表的编制及信效度检验[J].护理研究，2024，38（01）：31-36.
[26] Li P, Zhang N, Xu X, et al. Development of a caregiver-reported scale for pediatric cancer financial toxicity(CRS-PCFT)[J]. Cancer Medicine, 2025, 14(04): e70675.
[27] Ohlsen T J D, Fredman G, Burgara J, et al. Development of a pediatric oncology financial toxicity outcome measure with content and face validity: the parent-reported instrument of costs and experiences with financial toxicity (PRICE) measure[J]. JCO Oncol Pract, 2026(OP2600655).
[28] Wright P, Smith A B, Keding A, et al. The social difficulties inventory(SDI): development of subscales and scoring guidance for staff[J]. Psycho-Oncology, 2011, 20(01): 36-43.
[29] Head B A, Faul A C. Development and validation of a scale to measure socioeconomic well-being in persons with cancer[J]. The Journal of Supportive Oncology, 2008, 6(04): 183-192.
[30] Prawitz A D, Garman E T, Sorhaindo B, et al. In charge financial distress/financial well-being scale: development, administration, and score interpretation[J]. Journal of Financial Counseling and Planning, 2006, 17: 34-50.
[31] Aaronson N K, Ahmedzai S, Bergman B, et al. The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology[J]. JNCI Journal of the National Cancer Institute, 1993, 85(05): 365-376.
[32] Cella D F, Tulsky D S, Gray G, et al. The functional assessment of cancer therapy scale: Development and validation of the general measure[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 1993, 11(03): 570-579.
[33] Thayaparan A J, Mahdi E. The patient satisfaction questionnaire short form(PSQ-18) as an adaptable, reliable, and validated tool for use in various settings[J]. Medical Education Online, 2013, 18: 21747.
[34] Financial hardship in survivorship care delivery-PubMed[EB/OL]. [2025-12-19]. https://pubmed.ncbi.nlm.nih.gov/34478512/.
[35] 罗静.患者报告结局的经济毒性综合评分量表的汉化、验证与应用研究[D].成都：电子科技大学，2024.
[36] 于慧会，毕雪，刘运泳.中文版癌症患者报告结局的经济毒性量表信度和效度研究[J].中华流行病学杂志，2017，38（08）：1118-1120.
[37] Witte J, Mehlis K, Surmann B, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2019, 30(07): 1061-1070.
[38] Gordon L G, Merollini K M D, Lowe A,et al. A systematic review of financial toxicity among cancer survivors: we can′t pay the co-pay[J]. The Patient, 2017, 10(03): 295-309.
[39] 李文豪，李晴，张天懿.中老年人家庭灾难性卫生支出影响因素研究[J].卫生经济研究，2025，42（12）：23-27.
[40] 周心怡，孙鑫，黄文凯，等.2021年中国人群可筛查癌症的疾病经济负担研究[J].卫生经济研究，2026，43（01）：26-30，36.
[41] 曹逸钦，张悦，王艳艳，等.消化系统癌症患者经济毒性的研究进展[J].卫生经济研究，2025，42（02）：41-45.

相似文献/References:

[1]庞华容,阴 骏,吕俭霞,等.脑胶质瘤患者经济毒性现状及其影响因素分析[J].卫生经济研究,2024,41(05):19.
　PANG Huarong,YIN Jun,LYU Jianxia,et al.Study on the Current Situation and Influencing Factors of Financial Toxicity in Patients with Brain Glioma[J].Journal Press of Health Economics Research,2024,41(09):19.
[2]曹逸钦,张 悦,王艳艳,等.消化系统癌症患者经济毒性的研究进展[J].卫生经济研究,2025,42(02):41.
　CAO Yiqin,ZHANG Yue,WANG Yanyan,et al.Research Progress on Financial Toxicity in Patients with Digestive System Cancer[J].Journal Press of Health Economics Research,2025,42(09):41.

更新日期/Last Update: 2026-09-02